COPENHAGEN (Reuters) – Weight-loss and diabetes drugmaker Novo Nordisk on Wednesday posted third-quarter operating profit in line with expectations and narrowed its full-year sales and profit guidance range.
“The sales growth is driven by increasing demand for our GLP-1-based diabetes and obesity treatments, and we are serving more patients than ever before,” CEO Lars Fruergaard Jorgensen said in a statement.
Novo said operating profit between July and September rose 26% to 33.8 billion Danish crowns ($4.86 billion) compared with 33.6 billion forecast by analysts in a poll gathered by the company.
(Reporting by Maggie Fick and Jacob Gronholt-Pedersen, editing by Terje Solsvik)
